A Randomized Open-Label Phase 2/3 Study Comparing Cobolimab + Dostarlimab+Docetaxel to Dostarlimab+Docetaxel to Docetaxel Alone in Participants with Advanced Nonsmall Cell Lung Cancer Who Have Progressed on Prior Anti-PD-(L)1 Therapy and Chemotherapy (Costar Lung)
Brief description of study
The purpose of the study is to compare cobolimab and dostarlimab and docetaxel to dostarlimab and docetaxel to docetaxel alone for safety, efficacy, and tolerability in participants with advanced Non small Cell Lung Cancer who have progressed on prior anti-PD-(L)1 therapy and chemotherapy. There will be three treatment arms for this study. The study drugs cobolimab and dostarlimab are investigational, which means that they have not been approved by the U.S Food and Drug Administration (FDA), the health authority that gives approval for new medicines to be prescribed in the United States, but the FDA has given its permission to test these agents in the current trial.
If you are registered as a volunteer, please log in to contact the study team/express interest in this study.
